Perioperative immunotherapy appears to be safe in the setting of resectable hepatocellular carcinoma, according to findings from an open-label phase 2 clinical trial.
Although circulating tumor DNA (ctDNA) tests are already marketed for this use, they provide no advantage over standard approaches, concludes a new review.
Long-term results from the Dutch PREOPANC trial confirm that neoadjuvant chemoradiotherapy conveys a survival advantage to patients with resectable and borderline resectable pancreatic cancer.
Data from nearly 100,000 US patients with small, differentiated thyroid cancers showed surgery produced significantly better overall survival compared with surveillance without immediate surgery.